Social media 'high priority' for FDA 2012, despite lack of 2012 guidance
This article was originally published in Scrip
Executive Summary
The list of new and revised guidelines that the US Food and Drug Administration is planning to publish in 2012 makes no mention of its long-awaited guidance on promotion of prescription drugs using social media tools. However, the agency has confirmed to Scrip's sister publication, Scrip Regulatory Affairs, that it has not put this topic on the backburner and that "policy and guidance development for promotion of FDA-regulated medical products using the Internet and social media tools are among our highest priorities".
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.